ElectroCore Inc (ECOR)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
$8.80+4.76%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
QuarterlyIQ Insights · ECOR
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
The Company is also introducing preliminary 2027 revenue guidance of 30% to 40% revenue growth over full year 2026 revenue and expects to achieve its first quarter with positive Adjusted EBITDA by th…
Stated in 1 of 3 supplied quarters. Management reported: “Full Year 2026 and Select 2027 Outlook The Company is revising its full-year 2026 revenue outlook to a range of $39 million to $42 million, from its prior guidance of greater than 30% revenue growth.” “The Company is also introducing preliminary 2027 revenue guidance of 30% to 40% revenue growth over full year 2026 revenue and expects to achieve its first quarter with positive Adjusted EBITDA by the end of 2027.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 29% of the time over the next year (vs 52% for the rest of the cohort, n=10118).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“The Company is also introducing preliminary 2027 revenue guidance of 30% to 40% revenue growth over full year 2026 revenue and expects to achieve its first quarter with positive Adjusted EBITDA by th…”
The Company is also introducing preliminary 2027 revenue guidance of 30% to 40% revenue growth over full year 2026 revenue and expects to achieve its first quarter with positive Adjusted EBITDA by th…
Stated in 1 of 3 supplied quarters. Management reported: “The Company is also introducing preliminary 2027 revenue guidance of 30% to 40% revenue growth over full year 2026 revenue and expects to achieve its first quarter with positive Adjusted EBITDA by the end of 2027.” “Adjusted EBITDA net loss in the third quarter of 2026 was $0.7 million, compared to an Adjusted EBITDA net loss of $2.0 million in the third quarter of 2025, an improvement of approximately $1.4 million, or 67%, year-over-year.”
“The Company is also introducing preliminary 2027 revenue guidance of 30% to 40% revenue growth over full year 2026 revenue and expects to achieve its first quarter with positive Adjusted EBITDA by th…”
Veterans Affairs Channel Continues to Drive Prescription Growth The VA continued to be the Company’s largest growth driver in the third quarter.
Stated in 1 of 3 supplied quarters. Management reported: “Veterans Affairs Channel Continues to Drive Prescription Growth The VA continued to be the Company’s largest growth driver in the third quarter.” “U.S. Prescription (Rx) revenue grew approximately 25% in the third quarter and 34% in the first nine months over the same periods last year.”
“Veterans Affairs Channel Continues to Drive Prescription Growth The VA continued to be the Company’s largest growth driver in the third quarter.”
Return on advertising spend improved 8% in third quarter 2026 over the same period in 2025, demonstrating our strategic shift in the second quarter of 2026 to allocate spending toward higher-converti…
Stated in 1 of 3 supplied quarters. Management reported: “Continued Focus on Truvaga Efficiency The Company made a deliberate shift in the quarter to de-emphasize low-return revenue in our consumer channel and continued making meaningful improvements in marketing efficiency despite a more competitive and costly advertising environment.” “Return on advertising spend improved 8% in third quarter 2026 over the same period in 2025, demonstrating our strategic shift in the second quarter of 2026 to allocate spending toward higher-converting audiences and channels, prioritizing efficiency over broader awareness and prospecting.”
“Return on advertising spend improved 8% in third quarter 2026 over the same period in 2025, demonstrating our strategic shift in the second quarter of 2026 to allocate spending toward higher-converti…”
Exhibit 99.1 electroCore, Inc. Appoints Joshua Lev and Mike Fox as Co-Chief Executive Officers Internal leadership appointments reflect the Company’s confidence in two exceptional leaders whose compl…
Stated in a supplied disclosure. Management reported: “Exhibit 99.1 electroCore, Inc. Appoints Joshua Lev and Mike Fox as Co-Chief Executive Officers Internal leadership appointments reflect the Company’s confidence in two exceptional leaders whose complementary strengths will enhance shareholder value ROCKAWAY, N.J., September 9, 2026 (GLOBE NEWSWIRE), electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company and leader in non-invasive vagus nerve stimulation technologies, today announced that it has appointed Joshua Lev and Mike Fox as Co-Chief Executive Officers and members of the Board of Directors, effective September 8, 2026.”
Over the trailing year it converted 0.78x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
7 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 43% of the time over the next year (vs 45% for the rest of the cohort, n=9530).
Not investment advice. As of 2026-11-05.